111,458 Shares in Twist Bioscience Corporation $TWST Purchased by Osterweis Capital Management Inc.

Osterweis Capital Management Inc. bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 111,458 shares of the company’s stock, valued at approximately $11,467,000.

A number of other institutional investors and hedge funds have also bought and sold shares of TWST. ARK Investment Management LLC grew its position in shares of Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after purchasing an additional 832,687 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares during the period. BlackRock Inc. bought a new position in Twist Bioscience in the 2nd quarter valued at about $600,191,000. EdgePoint Investment Group Inc. increased its stake in Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after buying an additional 538,755 shares in the last quarter.

Twist Bioscience Trading Down 3.3%

Shares of TWST stock opened at $140.80 on Tuesday. The company has a market capitalization of $8.83 billion, a price-to-earnings ratio of -63.42 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a 50-day simple moving average of $101.89 and a two-hundred day simple moving average of $71.16. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $145.93.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter last year, the business posted $0.33 earnings per share. The business’s revenue was up 23.2% compared to the same quarter last year. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares in the company, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 151,529 shares of company stock worth $17,708,772. Company insiders own 3.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. UBS Group set a $89.00 price objective on Twist Bioscience in a research report on Monday, June 15th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Piper Sandler boosted their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Finally, Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a research report on Thursday, July 16th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.